RNS Number : 2703V
Genedrive PLC
05 April 2019

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 1,330,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
a.	*Name*	***David Budd*** *CEO* ***Matthew Fowler*** *CFO* ***Gino Miele*** *R&D Director* ***Gordon Powell*** *Commercial Director* ***Colleen Pythian*** *Director of Quality & Regulation* ***Warren Berry*** *Operations Director*
2.	***Reason for the notification***	
a.	*Position/status*	***1.***
a.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
a.	*Name*	*genedrive plc*
b.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
a.	*Description of the Financial instrument, type of instrument Identification code*	*Options over ordinary shares of 1.5 pence each*
b.	*Nature of the transaction*	*Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November*

<table>
<tr><td></td><td></td><td>2017.</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td>
<table>
<tr><th></th><th>Option price(s)</th><th>Volume(s)</th></tr>
<tr><td>David Budd</td><td>23.5p</td><td>540,000</td></tr>
<tr><td>Matthew Fowler</td><td>23.5p</td><td>340,000</td></tr>
<tr><td>Gino Miele</td><td>23.5p</td><td>150,000</td></tr>
<tr><td>Gordon Powell</td><td>23.5p</td><td>150,000</td></tr>
<tr><td>Colleen Pythian</td><td>23.5p</td><td>75,000</td></tr>
<tr><td>Warren Berry</td><td>23.5p</td><td>75,000</td></tr>
</table>
</td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>N/A</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>2019-April-04; UTC time</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options</td></tr>
</table>

For further details please contact:

genedrive plc +44 (0)161 989 0245

David Budd: CEO

Matthew Fowler: CFO

Peel Hunt LLP +44 (0)207 418 8900

James Steel / Oliver Jackson

Stanford Capital Partners Limited +44 (0) 20 3815 8880

Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAXLSEAPNEEF